Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1970 1
1978 1
1984 2
1985 2
1986 1
1987 3
1991 3
1992 11
1993 9
1994 13
1995 4
1996 5
1997 5
1998 1
2001 1
2002 1
2003 2
2004 4
2005 6
2006 4
2007 2
2008 4
2009 2
2010 5
2011 8
2012 6
2013 7
2014 6
2015 5
2016 4
2017 1
2018 2
2019 5
2020 2
2021 5
2022 2
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. N Engl J Med. 2013. PMID: 23228172 Free PMC article. Clinical Trial.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I Jr, Agarwal N. Goldkorn A, et al. Among authors: pinski jk. JAMA Netw Open. 2024 Oct 1;7(10):e2437871. doi: 10.1001/jamanetworkopen.2024.37871. JAMA Netw Open. 2024. PMID: 39374015 Free PMC article. Clinical Trial.
Nuclear Medicine Scans in Total Joint Replacement.
Pinski JM, Chen AF, Estok DM, Kavolus JJ. Pinski JM, et al. J Bone Joint Surg Am. 2021 Feb 17;103(4):359-372. doi: 10.2106/JBJS.20.00301. J Bone Joint Surg Am. 2021. PMID: 33369983 Review.
A BLIND STUDY.
EPSTEIN E, PINSKI JB. EPSTEIN E, et al. Among authors: pinski jb. Arch Dermatol. 1964 Apr;89:548-9. doi: 10.1001/archderm.1964.01590280048008. Arch Dermatol. 1964. PMID: 14107620 No abstract available.
Liposuction for lipomas.
Rubenstein R, Roenigk HH Jr, Garden JM, Goldberg NS, Pinski JB. Rubenstein R, et al. Among authors: pinski jb. J Dermatol Surg Oncol. 1985 Nov;11(11):1070-4. doi: 10.1111/j.1524-4725.1985.tb01395.x. J Dermatol Surg Oncol. 1985. PMID: 4056191
140 results